Last reviewed · How we verify
Lipidomic analyses
At a glance
| Generic name | Lipidomic analyses |
|---|---|
| Sponsor | Centre Georges Francois Leclerc |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Kaempferol Absorption and Pharmacokinetics Evaluation (NA)
- Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
- Goat Milk-Derived Formula vs. Undiluted Goat Milk in Infants Unable to Exclusively Breastfeed: Growth and Biomarker Analysis (NA)
- Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening (NA)
- Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer (PHASE2)
- Flemish Joint Effort for Biomarker PRofiling in Inflammatory Systemic Diseases (NA)
- Mechanisms of Type 1 Diabetes Endophenotypes
- Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipidomic analyses CI brief — competitive landscape report
- Lipidomic analyses updates RSS · CI watch RSS
- Centre Georges Francois Leclerc portfolio CI